Table of Contents
<< Previous Issue | Oct 2015 (Vol: 2015, Issue: 10) | Next Issue >> |
- Section: Licensing
-
Astellas Pays US$300 M Upfront to Access Immunomic’s LAMP-vax™ Platform
-
Novartis Comes to the Rescue of Xoma with TGFb Antibody Licensing Deal
- Section: Mergers & Acquisitions
-
BioMarin Exits Oncology Sector by Selling Talazoparib to Medivation in US$570 M Deal
-
BMS Fuels its Fibrotic Disease Pipeline with US$1.25 B Deal for Promedior